---
_id: '6659'
author:
- first_name: Carsten
  full_name: Lukas, Carsten
  last_name: Lukas
- first_name: Barbara
  full_name: Bellenberg, Barbara
  last_name: Bellenberg
- first_name: Horst K.
  full_name: Hahn, Horst K.
  last_name: Hahn
- first_name: Jan
  full_name: Rexilius, Jan
  id: '245736'
  last_name: Rexilius
  orcid: 0000-0002-4579-214X
  orcid_put_code_url: https://api.orcid.org/v2.0/0000-0002-4579-214X/work/207121134
- first_name: Robert
  full_name: Drescher, Robert
  last_name: Drescher
- first_name: Kerstin
  full_name: Hellwig, Kerstin
  last_name: Hellwig
- first_name: Odo
  full_name: Köster, Odo
  last_name: Köster
- first_name: Sebastian
  full_name: Schimrigk, Sebastian
  last_name: Schimrigk
citation:
  alphadin: '<span style="font-variant:small-caps;">Lukas, Carsten</span> ; <span
    style="font-variant:small-caps;">Bellenberg, Barbara</span> ; <span style="font-variant:small-caps;">Hahn,
    Horst K.</span> ; <span style="font-variant:small-caps;">Rexilius, Jan</span>
    ; <span style="font-variant:small-caps;">Drescher, Robert</span> ; <span style="font-variant:small-caps;">Hellwig,
    Kerstin</span> ; <span style="font-variant:small-caps;">Köster, Odo</span> ; <span
    style="font-variant:small-caps;">Schimrigk, Sebastian</span>: Benefit of repetitive
    intrathecal triamcinolone acetonide therapy in predominantly spinal multiple sclerosis:
    prediction by upper spinal cord atrophy. In: <i>Therapeutic Advances in Neurological
    Disorders</i> Bd. 2, SAGE Publications (2009), Nr. 6, S. 349–355'
  ama: 'Lukas C, Bellenberg B, Hahn HK, et al. Benefit of repetitive intrathecal triamcinolone
    acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper
    spinal cord atrophy. <i>Therapeutic Advances in Neurological Disorders</i>. 2009;2(6):349-355.
    doi:<a href="https://doi.org/10.1177/1756285609343480">10.1177/1756285609343480</a>'
  apa: 'Lukas, C., Bellenberg, B., Hahn, H. K., Rexilius, J., Drescher, R., Hellwig,
    K., … Schimrigk, S. (2009). Benefit of repetitive intrathecal triamcinolone acetonide
    therapy in predominantly spinal multiple sclerosis: prediction by upper spinal
    cord atrophy. <i>Therapeutic Advances in Neurological Disorders</i>, <i>2</i>(6),
    349–355. <a href="https://doi.org/10.1177/1756285609343480">https://doi.org/10.1177/1756285609343480</a>'
  bibtex: '@article{Lukas_Bellenberg_Hahn_Rexilius_Drescher_Hellwig_Köster_Schimrigk_2009,
    title={Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly
    spinal multiple sclerosis: prediction by upper spinal cord atrophy}, volume={2},
    DOI={<a href="https://doi.org/10.1177/1756285609343480">10.1177/1756285609343480</a>},
    number={6}, journal={Therapeutic Advances in Neurological Disorders}, publisher={SAGE
    Publications}, author={Lukas, Carsten and Bellenberg, Barbara and Hahn, Horst
    K. and Rexilius, Jan and Drescher, Robert and Hellwig, Kerstin and Köster, Odo
    and Schimrigk, Sebastian}, year={2009}, pages={349–355} }'
  chicago: 'Lukas, Carsten, Barbara Bellenberg, Horst K. Hahn, Jan Rexilius, Robert
    Drescher, Kerstin Hellwig, Odo Köster, and Sebastian Schimrigk. “Benefit of Repetitive
    Intrathecal Triamcinolone Acetonide Therapy in Predominantly Spinal Multiple Sclerosis:
    Prediction by Upper Spinal Cord Atrophy.” <i>Therapeutic Advances in Neurological
    Disorders</i> 2, no. 6 (2009): 349–55. <a href="https://doi.org/10.1177/1756285609343480">https://doi.org/10.1177/1756285609343480</a>.'
  ieee: 'C. Lukas <i>et al.</i>, “Benefit of repetitive intrathecal triamcinolone
    acetonide therapy in predominantly spinal multiple sclerosis: prediction by upper
    spinal cord atrophy,” <i>Therapeutic Advances in Neurological Disorders</i>, vol.
    2, no. 6, pp. 349–355, 2009.'
  mla: 'Lukas, Carsten, et al. “Benefit of Repetitive Intrathecal Triamcinolone Acetonide
    Therapy in Predominantly Spinal Multiple Sclerosis: Prediction by Upper Spinal
    Cord Atrophy.” <i>Therapeutic Advances in Neurological Disorders</i>, vol. 2,
    no. 6, SAGE Publications, 2009, pp. 349–55, doi:<a href="https://doi.org/10.1177/1756285609343480">10.1177/1756285609343480</a>.'
  short: C. Lukas, B. Bellenberg, H.K. Hahn, J. Rexilius, R. Drescher, K. Hellwig,
    O. Köster, S. Schimrigk, Therapeutic Advances in Neurological Disorders 2 (2009)
    349–355.
date_created: 2026-03-02T10:03:31Z
date_updated: 2026-03-17T15:29:33Z
doi: 10.1177/1756285609343480
intvolume: '         2'
issue: '6'
language:
- iso: eng
page: 349-355
publication: Therapeutic Advances in Neurological Disorders
publication_identifier:
  eissn:
  - 1756-2864
  issn:
  - 1756-2864
publication_status: published
publisher: SAGE Publications
quality_controlled: '1'
status: public
title: 'Benefit of repetitive intrathecal triamcinolone acetonide therapy in predominantly
  spinal multiple sclerosis: prediction by upper spinal cord atrophy'
type: journal_article
user_id: '220548'
volume: 2
year: '2009'
...